Suchergebnisse - "Aromatase Inhibitors/adverse effects"
-
1
Autoren: et al.
Quelle: CAPItello-291 Study Group 2023, 'Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer', The New England Journal of Medicine, vol. 388, no. 22, pp. 2058-2070. https://doi.org/10.1056/NEJMoa2214131
Schlagwörter: Male, Aromatase Inhibitors, Receptor, ErbB-2, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Breast Neoplasms, 3. Good health, Local/drug therapy, Neoplasm Recurrence, Local/drug therapy, Neoplasm Recurrence, ErbB-2, Breast Neoplasms/drug therapy, Double-Blind Method, Antineoplastic Combined Chemotherapy Protocols, Fulvestrant/adverse effects, Humans, Female, Aromatase Inhibitors/adverse effects, Neoplasm Recurrence, Local, Fulvestrant, Proto-Oncogene Proteins c-akt, Receptor
-
2
Autoren: et al.
Quelle: Blood Adv
Schlagwörter: Male, Breast Neoplasms / drug therapy, Aromatase Inhibitors, Venous Thromboembolism / chemically induced, Thrombin, Breast Neoplasms, Venous Thromboembolism, Thrombosis and Hemostasis, 3. Good health, Tamoxifen, 03 medical and health sciences, 0302 clinical medicine, Aromatase Inhibitors / adverse effects, Tamoxifen / adverse effects, Humans, Female, Prospective Studies, Protein C
Dateibeschreibung: application/pdf
-
3
Autoren: et al.
Weitere Verfasser: et al.
Quelle: Lancet Oncol
Bradley, R, Braybrooke, J, Gray, R, Hills, R K, Liu, Z, Pan, H, Peto, R, Dodwell, D, McGale, P, Taylor, C, Francis, P A, Gnant, M, Perrone, F, Regan, M M, Berry, R, Boddington, C, Clarke, M, Davies, C, Davies, L, Duane, F, Evans, V, Gay, J, Gettins, L, Godwin, J, James, S, Liu, H, MacKinnon, E, Mannu, G, McHugh, T, Morris, P, Read, S, Straiton, E, Jakesz, R, Fesl, C, Pagani, O, Gelber, R, De Laurentiis, M, De Placido, S, Gallo, C, Albain, K, Anderson, S, Arriagada, R, Bartlett, J, Bergsten-Nordström, E, Bliss, J, Brain, E, Carey, L, Coleman, R, Cuzick, J, Ejlertsen, B & Early Breast Cancer Trialists' Collaborative Group (EBCTCG) 2022, ' Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression : a patient-level meta-analysis of 7030 women from four randomised trials ', The Lancet Oncology, vol. 23, no. 3, pp. 382-392 . https://doi.org/10.1016/S1470-2045(21)00758-0
Bradley, R, Braybrooke, J, Gray, R, Hills, R K, Liu, Z, Pan, H, Peto, R, Dodwell, D, Mcgale, P, Taylor, C, Francis, P A, Gnant, M, Perrone, F, Regan, M M, Berry, R, Boddington, C, Clarke, M, Davies, C, Davies, L, Duane, F, Evans, V, Gay, J, Gettins, L, Godwin, J, James, S, Liu, H, Mackinnon, E, Mannu, G, Mchugh, T, Morris, P, Read, S, Straiton, E, Jakesz, R, Fesl, C, Pagani, O, Gelber, R, De Laurentiis, M, De Placido, S, Gallo, C, Albain, K, Anderson, S, Arriagada, R, Bartlett, J, Bergsten-nordström, E, Bliss, J, Brain, E, Carey, L, Coleman, R, Cuzick, J, Davidson, N, Del Mastro, L, Di Leo, A, Dignam, J, Dowsett, M, Ejlertsen, B, Goetz, M, Goodwin, P, Halpin-murphy, P, Hayes, D, Hill, C, Jagsi, R, Janni, W, Loibl, S, Mamounas, E P, Martín, M, Mukai, H, Nekljudova, V, Norton, L, Ohashi, Y, Pierce, L, Poortmans, P, Pritchard, K I, Raina, V, Rea, D, Robertson, J, Rutgers, E, Spanic, T, Sparano, J, Steger, G, Tang, G, Toi, M, Tutt, A, Viale, G, Wang, X, Whelan, T, Wilcken, N, Wolmark, N, Cameron, D, Bergh, J & Swain, S M 2022, ' Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials ', The Lancet Oncology, vol. 23, no. 3, pp. 382-392 . https://doi.org/10.1016/S1470-2045(21)00758-0Schlagwörter: Breast Neoplasms/pathology, Antineoplastic Agents, Hormonal/therapeutic use, Antineoplastic Agents, Hormonal, Antineoplastic Agents, Breast Neoplasms, 03 medical and health sciences, 0302 clinical medicine, Receptors, Chemotherapy, Humans, Adjuvant, Randomized Controlled Trials as Topic, Hormonal, Aromatase Inhibitors, Articles, Estrogen, 3. Good health, Tamoxifen, Neoplasm Recurrence, Local/drug therapy, Neoplasm Recurrence, Tamoxifen/therapeutic use, Local, Receptors, Estrogen, Chemotherapy, Adjuvant, Female, Aromatase Inhibitors/adverse effects, Neoplasm Recurrence, Local
Dateibeschreibung: application/pdf
Zugangs-URL: http://www.thelancet.com/article/S1470204521007580/pdf
https://pubmed.ncbi.nlm.nih.gov/35123662
http://hdl.handle.net/11588/890570
https://curis.ku.dk/ws/files/314836495/1_s2.0_S1470204521007580_main.pdf
https://www.pure.ed.ac.uk/ws/files/251776506/PIIS1470204521007580.pdf
https://hdl.handle.net/20.500.11820/cca1ad07-b6fb-4d9f-a5f5-d418002b61da
https://hdl.handle.net/11567/1156767
https://doi.org/10.1016/S1470-2045(21)00758-0
https://hdl.handle.net/11588/890570
https://doi.org/10.1016/S1470-2045(21)00758-0 -
4
Autoren: et al.
Weitere Verfasser: et al.
Quelle: PARAGON investigators 2021, 'Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus : The PARAGON trial (ANZGOG 0903)', Gynecologic Oncology, vol. 163, no. 3, pp. 524-530. https://doi.org/10.1016/j.ygyno.2021.09.010
Schlagwörter: Adult, Leiomyosarcoma, 0301 basic medicine, Carcinosarcoma/drug therapy, Receptors, Progesterone/metabolism, Sustainable Development Goals, Anastrozole, uterine carcinosarcoma, uterine leiomyosarcoma, 03 medical and health sciences, 0302 clinical medicine, Carcinosarcoma, Uterine Neoplasms/drug therapy, Uterine leiomyosarcoma, Receptors, 80 and over, Humans, Prospective Studies, Neoplasm Metastasis, SDG 3, Aged, Aged, 80 and over, Manchester Cancer Research Centre, Uterine carcinosarcoma, Aromatase Inhibitors, Leiomyosarcoma/drug therapy, Anastrozole/adverse effects, Aromatase inhibitor, Middle Aged, ResearchInstitutes_Networks_Beacons/mcrc, name=Manchester Cancer Research Centre, 3. Good health, Receptors, Estrogen, aromatase inhibitor, Uterine Neoplasms, Quality of Life, Progesterone/metabolism, Female, Aromatase Inhibitors/adverse effects, Estrogen/metabolism, Receptors, Estrogen/metabolism, Receptors, Progesterone
Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/34625284
https://research.manchester.ac.uk/en/publications/a4447fca-4b40-4043-bd44-5f411c01edde
https://doi.org/10.1016/j.ygyno.2021.09.010
https://chesterrep.openrepository.com/handle/10034/626171
https://www.sciencedirect.com/science/article/pii/S0090825821013792
https://pubmed.ncbi.nlm.nih.gov/34625284/
https://www.gynecologiconcology-online.net/article/S0090-8258(21)01379-2/fulltext -
5
Autoren: et al.
Weitere Verfasser: et al.
Quelle: Cancer Sci
Schlagwörter: Breast Neoplasms / blood, Aminopyridines / adverse effects, Receptor, ErbB-2, Benzimidazoles / administration & dosage, Aminopyridines, abemaciclib, Fulvestrant / administration & dosage, 0302 clinical medicine, Anastrozole / adverse effects, Aminopyridines / pharmacokinetics, East Asia, Neutropenia / chemically induced, Fulvestrant, Letrozole / administration & dosage, Aromatase Inhibitors, Benzimidazoles / pharmacokinetics, Letrozole / adverse effects, ErbB-2 / genetics, Aminopyridines / administration & dosage, metastatic, 3. Good health, Aromatase Inhibitors / administration & dosage, Treatment Outcome, Aromatase Inhibitors / adverse effects, Anastrozole / administration & dosage, Combination, Letrozole, Neutropenia / epidemiology, Drug Therapy, Combination, Female, Anastrozole / pharmacokinetics, Receptor, Benzimidazoles / adverse effects, Diarrhea, Breast Neoplasms / drug therapy, Neutropenia, Fulvestrant / adverse effects, Breast Neoplasms, Anastrozole, Fulvestrant / pharmacokinetics, 03 medical and health sciences, breast cancer, Drug Therapy, Double-Blind Method, Diarrhea / epidemiology, Humans, Letrozole / pharmacokinetics, cyclin-dependent kinase inhibitor, Diarrhea / chemically induced, Original Articles, Breast Neoplasms / genetics, Aromatase Inhibitors / pharmacokinetics, Benzimidazoles
Zugangs-URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/cas.14877
https://pubmed.ncbi.nlm.nih.gov/33686753
https://mayoclinic.pure.elsevier.com/en/publications/abemaciclib-in-combination-with-endocrine-therapy-for-east-asian-
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8177785/
https://onlinelibrary.wiley.com/doi/10.1111/cas.14877
https://snucm.elsevierpure.com/en/publications/abemaciclib-in-combination-with-endocrine-therapy-for-east-asian-
https://europepmc.org/article/MED/33686753
https://pubmed.ncbi.nlm.nih.gov/33686753/ -
6
Autoren: et al.
Weitere Verfasser: et al.
Schlagwörter: Antineoplastic Agents, Hormonal/administration & dosage, Hormonal/adverse effects, Aromatase Inhibitors/administration & dosage, Aromatase Inhibitors/adverse effects, Breast Neoplasms/drug therapy, Chemotherapy, Adjuvant, Disease-Free Survival, Double-Blind Method, Drug Administration Schedule, Female, Follow-Up Studies, Fractures, Bone/epidemiology, Humans, Incidence, Kaplan-Meier Estimate, Neoplasm Recurrence, Local/prevention & control, Nitriles/administration & dosage, Nitriles/adverse effects, Postmenopause, Proportional Hazards Models, Tamoxifen/administration & dosage, Tamoxifen/adverse effects, Triazoles/administration & dosage, Triazoles/adverse effects
Relation: New England Journal of Medicine; https://iris.unil.ch/handle/iris/47611; serval:BIB_3F68E32EDDEA; 000269081200005
-
7
Autoren: et al.
Weitere Verfasser: et al.
Schlagwörter: Aged, 80 and over, Antineoplastic Agents, Hormonal/administration & dosage, Hormonal/adverse effects, Aromatase Inhibitors/administration & dosage, Aromatase Inhibitors/adverse effects, Breast Neoplasms/drug therapy, Disease-Free Survival, Double-Blind Method, Female, Humans, Menopause, Middle Aged, Nitriles/administration & dosage, Nitriles/adverse effects, Postmenopause, Tamoxifen/administration & dosage, Tamoxifen/adverse effects, Triazoles/administration & dosage, Triazoles/adverse effects
Relation: Breast Cancer Research and Treatment; https://iris.unil.ch/handle/iris/109694; serval:BIB_36EB346B01DA; 000298006300030
-
8
Autoren: et al.
Quelle: Frontiers in endocrinology, 12:713700
Schlagwörter: Chemoprevention [MeSH], Female [MeSH], breast cancer, Bone Density/drug effects [MeSH], Humans [MeSH], Arthralgia/chemically induced [MeSH], Breast Neoplasms/drug therapy [MeSH], Breast Neoplasms/chemistry [MeSH], Musculoskeletal Diseases/chemically induced [MeSH], Risk Factors [MeSH], aromatase inhibitor-induced arthralgia, Body Mass Index [MeSH], Musculoskeletal Diseases/therapy [MeSH], Aromatase Inhibitors/therapeutic use [MeSH], aromatase inhibitor, Breast Neoplasms/prevention, aromatase inhibitor-associated musculoskeletal syndrome, Aromatase Inhibitors/adverse effects [MeSH], Musculoskeletal Diseases/epidemiology [MeSH], Endocrinology, Receptors, Estrogen/analysis [MeSH], aromatase inhibitor-induced bone loss
Relation: https://repository.publisso.de/resource/frl:6478967; https://doi.org/10.3389/fendo.2021.713700; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8353230/
-
9
Autoren: et al.
Quelle: JAMA Netw Open
Harborg, S, Cronin-Fenton, D, Jensen, M-B R, Ahern, T P, Ewertz, M & Borgquist, S 2023, 'Obesity and Risk of Recurrence in Patients With Breast Cancer Treated With Aromatase Inhibitors', JAMA network open, vol. 6, no. 10, e2337780. https://doi.org/10.1001/jamanetworkopen.2023.37780Schlagwörter: 2. Zero hunger, Neoplasm Recurrence, Local/epidemiology, Aromatase Inhibitors, Breast Neoplasms/diagnosis, Breast Neoplasms, Middle Aged, Overweight, 3. Good health, Overweight/complications, Obesity, Morbid, Obesity, Morbid/complications, Cohort Studies, Humans, Female, Aromatase Inhibitors/adverse effects, Obesity, Obesity/complications, Neoplasm Recurrence, Local, Original Investigation, Aged
Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/37831449
-
10
Autoren: et al.
Weitere Verfasser: et al.
Quelle: European Journal of Cancer. 82:103-114
Schlagwörter: Adult, 0301 basic medicine, Hepatic steatosis, Antineoplastic Agents, Hormonal, Lipids/blood, Antineoplastic Agents, Breast Neoplasms, Anastrozole, Fatty Liver/chemically induced, Triglyceride, Tamoxifen/adverse effects, 03 medical and health sciences, Adjuvant endocrine therapy, High-density lipoprotein cholesterol, Nitriles, Chemotherapy, Humans, Adjuvant/adverse effects, 14. Life underwater, Fatty Liver/epidemiology, Propensity Score, Aged, Retrospective Studies, 2. Zero hunger, Aromatase Inhibitors, Incidence, Nitriles/adverse effects, Hormonal/adverse effects, Middle Aged, Triazoles, Lipids, 3. Good health, Fatty Liver, Tamoxifen, Aromatase Inhibitors/adverse effects, Chemotherapy, Adjuvant, Breast Neoplasms/drug therapy, Letrozole, Female, Biomarkers/blood, Biomarkers, Triazoles/adverse effects
Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/28651157
https://www.sciencedirect.com/science/article/abs/pii/S0959804917309346
https://ir.ymlib.yonsei.ac.kr/handle/22282913/154215
https://pubmed.ncbi.nlm.nih.gov/28651157/
https://www.ncbi.nlm.nih.gov/pubmed/28651157
http://europepmc.org/abstract/MED/28651157 -
11
Autoren: et al.
Weitere Verfasser: et al.
Quelle: Archives of Toxicology
Schlagwörter: 0301 basic medicine, 0303 health sciences, Adverse Outcome Pathways, Aromatase Inhibitors, risk assessment, Proteins, Toxicology, Ecotoxicology, Risk Assessment, adverse outcome pathway, ecotoxicology, Ecotoxicology/methods, 3. Good health, 03 medical and health sciences, Skin/drug effects, Proteins/metabolism, Animals, Humans, Aromatase Inhibitors/adverse effects, 10. No inequality, Skin
Zugangs-URL: https://europepmc.org/articles/pmc5805086?pdf=render
https://pubmed.ncbi.nlm.nih.gov/28660287
https://researchportal.vub.be/en/publications/adverse -outcome-pathways-a-concise-introduction-for-toxicologists
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5805086/
https://link.springer.com/article/10.1007%2Fs00204-017-2020-z
https://europepmc.org/articles/PMC5805086
https://pubmed.ncbi.nlm.nih.gov/28660287/
https://rd.springer.com/article/10.1007/s00204-017-2020-z
https://biblio.vub.ac.be/vubir/adverse -outcome-pathways-a-concise-introduction-for-toxicologists(faf1d8e5-5617-4059-b243-91cfdcbf3905).html -
12
Autoren: et al.
Weitere Verfasser: et al.
Quelle: Cancer Res Treat
Schlagwörter: Receptor, ErbB-2, Aromatase Inhibitors / therapeutic use, Triazoles / therapeutic use, Kaplan-Meier Estimate, Nitriles / therapeutic use, Triazoles / administration & dosage, 0302 clinical medicine, Receptors, 80 and over, Nitriles / adverse effects, Neoplasm Metastasis, Aged, 80 and over, Tumor, Antineoplastic Agents / administration & dosage, Breast Neoplasms / mortality, Aromatase Inhibitors, Middle Aged, Metastatic breast cancer, Combined Modality Therapy, Triazoles / adverse effects, 3. Good health, Postmenopause, Treatment Outcome, Aromatase Inhibitors / adverse effects, Receptors, Estrogen, Estrogen / metabolism, Letrozole, Breast Neoplasms / pathology, Original Article, Female, Receptors, Progesterone, Receptor, Adult, Breast Neoplasms / drug therapy, First-line treatment, Antineoplastic Agents, Breast Neoplasms, Antineoplastic Agents / therapeutic use, 03 medical and health sciences, Aromatase Inhibitors / administration & dosage, Republic of Korea, Nitriles, Hormone receptor-positive, Biomarkers, Tumor, Humans, Nitriles / administration & dosage, Aged, Korea, Antineoplastic Agents / adverse effects, Breast Neoplasms / metabolism, Progesterone / metabolism, Survival Analysis, ErbB-2 / metabolism, Biomarkers, Follow-Up Studies
Zugangs-URL: http://www.e-crt.org/upload/pdf/crt-2016-259.pdf
https://pubmed.ncbi.nlm.nih.gov/27554482
https://ir.ymlib.yonsei.ac.kr/handle/22282913/178314
http://europepmc.org/articles/PMC5398408
https://www.e-crt.org/journal/view.php?doi=10.4143/crt.2016.259
https://snucm.elsevierpure.com/en/publications/efficacy-of-letrozole-as-first-line-treatment-of-postmenopausal-w
http://www.e-crt.org/upload/pdf/crt-2016-259.pdf
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5398408 -
13
Autoren: et al.
Weitere Verfasser: et al.
Quelle: Supportive Care in Cancer. 25:1673-1686
Schlagwörter: Aromatase Inhibitors, Breast Neoplasms, Review, Arthralgia, 3. Good health, Arthralgia/chemically induced, 03 medical and health sciences, Treatment Outcome, 0302 clinical medicine, Breast Neoplasms/drug therapy, Prevalence, Humans, Female, Aromatase Inhibitors/adverse effects
Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/28204994
https://pubmed.ncbi.nlm.nih.gov/28204994/
https://link.springer.com/article/10.1007/s00520-017-3613-z
https://researchportal.vub.be/en/publications/prevalence-of-aromatase -inhibitor-induced-arthralgia-in-breast-ca
https://www.ncbi.nlm.nih.gov/pubmed/28204994
https://europepmc.org/article/MED/28204994
https://biblio.vub.ac.be/vubir/(9a457c27-5275-40ff-8a75-2ec9668f86fd).html -
14
Weitere Verfasser: et al.
Schlagwörter: Adolescent, Adult, Age Factors, Aged, 80 and over, Antineoplastic Agents, Hormonal/administration & dosage, Hormonal/adverse effects, Hormonal/therapeutic use, Aromatase Inhibitors/administration & dosage, Aromatase Inhibitors/adverse effects, Aromatase Inhibitors/therapeutic use, Drug Therapy, Combination, Endometrium/pathology, Female, Humans, Insurance Claim Review/statistics & numerical data, Middle Aged, Postmenopause, Progression-Free Survival, Proportional Hazards Models, Republic of Korea/epidemiology, Retrospective Studies, Tamoxifen/administration & dosage, Tamoxifen/adverse effects, Tamoxifen/therapeutic use, Young Adult
Relation: MEDICINE; J02214; https://ir.ymlib.yonsei.ac.kr/handle/22282913/167545; T201900200; 42881
-
15
Autoren: et al.
Weitere Verfasser: et al.
Quelle: Calcified Tissue International. 97:551-559
Schlagwörter: Breast Neoplasms, Bone strength, 03 medical and health sciences, Breast cancer, 0302 clinical medicine, Bone Density, Humans, Femur Neck/drug effects, Quantitative computed tomography, Tomography, 2. Zero hunger, Bone geometry, Aromatase Inhibitors, Femur Neck, Bone Density/drug effects, Aromatase inhibitor, Middle Aged, X-Ray Computed, 3. Good health, Femur Neck/diagnostic imaging, Postmenopause, Aromatase Inhibitors/adverse effects, Cross-Sectional Studies, Breast Neoplasms/drug therapy, Female, Tomography, X-Ray Computed
Dateibeschreibung: 551~559
Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/26232103
-
16
Autoren: et al.
Weitere Verfasser: et al.
Quelle: The Breast. 22:1205-1209
Schlagwörter: Breast Neoplasms/pathology, Kaplan-Meier Estimate, PR, progesterone receptor, PFS, Palliative Care, Breast cancer, 0302 clinical medicine, MHT, Receptors, Progesterone/analysis, Neoplasm Metastasis, progression free survival, Antineoplastic Agents/therapeutic use, Aromatase Inhibitors, Aromatase Inhibitors/therapeutic use, Selective Estrogen Receptor Modulators/adverse effects, Selective Estrogen Receptor Modulators/therapeutic use, OS, Middle Aged, 3. Good health, Receptors, Estrogen, Estrogen/analysis, Breast Neoplasms/drug therapy, Female, metastatic breast cancer, Receptors, Progesterone, estrogen receptor, Adult, Selective Estrogen Receptor Modulators, MBC, Maintenance, overall survival, Antineoplastic Agents, Breast Neoplasms, Disease-Free Survival, Maintenance Chemotherapy, medroxyprogesteron acetate, 03 medical and health sciences, Humans, Hormone therapy, Aged, Retrospective Studies, maintenance hormone therapy, response evaluation criteria in solid tumors, Antineoplastic Agents/adverse effects, Breast Neoplasms/chemistry, MPA, ER, RECIST, Aromatase Inhibitors/adverse effects
Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/24135766
http://europepmc.org/abstract/MED/24135766
https://ir.ymlib.yonsei.ac.kr/handle/22282913/88927
https://www.ncbi.nlm.nih.gov/pubmed/24135766
https://pubmed.ncbi.nlm.nih.gov/24135766/
https://mdanderson.elsevierpure.com/en/publications/prolonged-clinical-benefit-from-the-maintenance-hormone-therapy-i
https://yonsei.pure.elsevier.com/en/publications/prolonged-clinical-benefit-from-the-maintenance-hormone-therapy-i -
17
Autoren: et al.
Quelle: Gynecological Endocrinology. 30:182-186
Schlagwörter: Neoplasms, Hormone-Dependent, fertility preservation, Estrogen Antagonists/adverse effects, cancer treatment, Estrogen Antagonists/pharmacology, Tamoxifen/adverse effects, Time-to-Treatment, Gonadotropins/pharmacology, Tamoxifen/pharmacology, 03 medical and health sciences, 0302 clinical medicine, Neoplasms, Hormone-Dependent/chemically induced, Ovulation Induction, Neoplasms, Nitriles, Neoplasms, Hormone-Dependent/therapy, Neoplasms/therapy, Humans, Precision Medicine, 2. Zero hunger, Aromatase Inhibitors/pharmacology, Triazoles/pharmacology, Aromatase Inhibitors, Nitriles/adverse effects, Gonadotropins/adverse effects, Estrogen Antagonists, Fertility Preservation, Triazoles, Ovulation Induction/methods, 3. Good health, Tamoxifen, Fertility Preservation/methods, Neoplasms/chemically induced, Nitriles/pharmacology, Letrozole, Ovulation Induction/adverse effects, Female, Aromatase Inhibitors/adverse effects, Gonadotropins, Triazoles/adverse effects
Dateibeschreibung: application/pdf
Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/24256369
http://informahealthcare.com/doi/abs/10.3109/09513590.2013.860123
https://doi.org/10.3109/09513590.2013.860123
http://medlib.mef.hr/id/eprint/2397
https://www.bib.irb.hr/671917
https://www.tandfonline.com/doi/full/10.3109/09513590.2013.860123
http://www.ncbi.nlm.nih.gov/pubmed/24256369
https://urn.nsk.hr/urn:nbn:hr:105:548960
https://doi.org/10.3109/09513590.2013.860123
http://doi.org/10.3109/09513590.2013.860123 -
18
Autoren: et al.
Weitere Verfasser: et al.
Quelle: Endocrine Journal. 60:167-172
Schlagwörter: Peptides/blood, Calcitriol/administration & dosage, Peptides/metabolism, 0302 clinical medicine, Bone Density, Breast Neoplasms/blood, Cholecalciferol, Alendronate, Bone Density Conservation Agents, Aromatase Inhibitors, Bone Density Conservation Agents/therapeutic use, Dietary/therapeutic use, Middle Aged, Combined Modality Therapy, Calcitriol/therapeutic use, 3. Good health, Postmenopause, Drug Combinations, Breast Neoplasms/drug therapy, Aromatse inhibitor, Combinative agent, Female, Cholecalciferol/therapeutic use, Breast Neoplasms/complications, Patient Dropouts, Bone Resorption/prevention & control, Collagen Type I/blood, Antineoplastic Agents, Breast Neoplasms, Collagen Type I/metabolism, Bone and Bones/metabolism, Bone and Bones, Collagen Type I, 03 medical and health sciences, Calcitriol, Double-Blind Method, Republic of Korea, Humans, Bone Resorption/chemically induced, Bone Resorption, Antineoplastic Agents/therapeutic use, Bone and Bones/drug effects, Postmenopausal/complications, Bone Density/drug effects, Alendronate/therapeutic use, Postmenopausal/diet therapy, Calcium, Dietary, Aromatase Inhibitors/adverse effects, Postmenopausal/drug therapy, Alendronate/administration & dosage, Breast Neoplasms/metabolism, Antineoplastic Agents/adverse effects, Dietary Supplements, Osteoporosis, Calcium, Biomarkers/blood, Biomarkers, Aromatase Inhibitors/therapeutic use
Zugangs-URL: https://www.jstage.jst.go.jp/article/endocrj/60/2/60_EJ12-0283/_pdf
https://pubmed.ncbi.nlm.nih.gov/23064476
https://yonsei.pure.elsevier.com/en/publications/efficacy-of-a-combined-alendronate-and-calcitriol-agent-maxmarvil
https://pubmed.ncbi.nlm.nih.gov/23064476/
https://www.jstage.jst.go.jp/article/endocrj/60/2/60_EJ12-0283/_article
https://europepmc.org/article/MED/23064476
https://ci.nii.ac.jp/naid/10031156737
https://ir.ymlib.yonsei.ac.kr/handle/22282913/88967 -
19
Autoren: et al.
Quelle: Läkartidningen. 114(7):298
-
20
Autoren: et al.
Quelle: Br J Cancer
British Journal of Cancer, 106 (10Schlagwörter: Quality of life, letrozole, Tamoxifen -- adverse effects, Breast Neoplasms, Estrogen Antagonists -- adverse effects, 03 medical and health sciences, breast cancer, Breast cancer, Cognition, 0302 clinical medicine, Nitriles, Humans, subjective cognitive function, Neoplasm Staging, Aromatase Inhibitors -- adverse effects, tamoxifen, Aromatase Inhibitors, Cognition -- drug effects, Estrogen Antagonists, Aromatase inhibitor, Triazoles, Breast Neoplasms -- drug therapy -- pathology -- psychology, Nitriles -- adverse effects, 3. Good health, Cancérologie, Subjective cognitive function, Tamoxifen, quality of life, Triazoles -- adverse effects, aromatase inhibitor, Letrozole, Clinical Study, Quality of Life, Female
Dateibeschreibung: 1 full-text file(s): application/pdf; application/pdf
Zugangs-URL: https://www.nature.com/articles/bjc2012156.pdf
https://pubmed.ncbi.nlm.nih.gov/22531635
https://dash.harvard.edu/handle/1/11178965
https://core.ac.uk/display/20454889
https://www.nature.com/articles/bjc2012156.pdf
https://mdanderson.elsevierpure.com/en/publications/subjective-cognitive-complaints-one-year-after-ceasing-adjuvant-e
https://moh-it.pure.elsevier.com/en/publications/subjective-cognitive-complaints-one-year-after-ceasing-adjuvant-e
https://minerva-access.unimelb.edu.au/handle/11343/265127
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/144332
Full Text Finder 
Nájsť tento článok vo Web of Science 
Full Text